O.B.E

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

Retrieved on: 
목요일, 3월 28, 2024
Internal medicine, University, Natural science, Biomedicine, Alphabet, Calico (company), Immune system, SAN, Research, Science, Whitehead Institute, National academy, Biology, Biochemistry, Johns Hopkins University, NIAID, Most, Nobel, Bangladesh Technical Education Board, Birth, Biomedical Research, O.B.E, Infection, Ageing, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer.
  • Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades.
  • "Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr. Levinson, CEO of Calico.
  • "The commitment to scientific excellence and integrity at Calico, coupled with the highly talented team, is truly impressive and reflected in the impactful progress they are making.

ISTH Congress to Return to In-Person in London July 9-13 with Virtual Component to Engage Global Participation

Retrieved on: 
화요일, 3월 29, 2022
Microangiopathy, SSC, Proteolysis, LOC, Congress, Vaccination, Diagnosis, Thrombosis, Hemostasis, Omics, International Society on Thrombosis and Haemostasis, Biotechnology, Research, Coagulopathy, Cancer, Health, Immunity, Poster, O.B.E, Fibrinolysis, Megakaryocyte, Documentation, Industry, Safety, Travel, International Society, ExCeL London, COVID-19, Embolism, Inflammation, Coagulation, International Accounting Standards Committee, Chair, Haemophilia, Science, Solution, Education, Patient, Pharmaceutical industry, ISTH

CHAPEL HILL, N.C., March 29, 2022 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH) announces today that the ISTH 2022 Congress will move forward as planned on July 9-13, 2022 at ExCel London in the U.K. with the first in-person component, in addition to hybrid and virtual options, since 2019 due to the two-year long Covid-19 pandemic.

Key Points: 
  • The ISTH Congress, the largest in the field of thrombosis and hemostasis, promotes important scientific discourse and advancement to improve the lives of patients in more than 110 countries around the world.
  • "The ISTH 2022 Congress will be a must-attend international meeting that features groundbreaking research and innovative advancements, as well as provides invaluable professional connections for those attending.
  • In addition to the in-person meeting, ISTH 2022 will feature a robust online platform for those unable to join onsite in an effort to include global participation.
  • Hosted live from London, it will feature all aspects of the Congress both live and recorded for virtual attendees.